Menovag (Estradiol)

Estradiol exerts its effect by binding to intracellular estrogen receptors (ERα and ERβ) within vaginal epithelial cells. The hormone‑receptor complex then moves to the cell nucleus, where it binds estrogen‑responsive DNA elements and modulates gene transcription. This leads to increased cellular proliferation, enhanced blood flow, and restoration of the mucosal barrier, counteracting the changes caused by estrogen deficiency.

The specific dose and regimen of Menovag are determined by the prescribing healthcare professional based on the individual’s severity of symptoms, medical history, and response to therapy. Physicians typically select a low‑dose vaginal formulation and adjust frequency as needed, following current clinical guidelines for hormone replacement therapy.

Estradiol is generally contraindicated during pregnancy because systemic absorption may affect fetal development, and its safety in breastfeeding has not been established. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative treatments with their clinician, as Menovag is intended for post‑menopausal use.

To place an order, submit an enquiry on the Menovag product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Menovag delivers estradiol directly to the vaginal mucosa, offering localized symptom relief with lower systemic exposure compared with oral or transdermal estrogen preparations. This route often results in fewer systemic side effects, such as cardiovascular risks, while providing effective treatment of urogenital atrophy. However, oral formulations may be preferred when systemic estrogen effects are also desired.

Menovag should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme temperatures or humidity, which could affect its stability and efficacy.

Menovag is inserted into the vagina using the supplied applicator or as directed by the prescriber. The typical administration involves placing the tablet or insert at bedtime, allowing it to dissolve and release estradiol locally. Patients should follow the specific instructions provided by their healthcare professional regarding frequency and duration of use.

Serious adverse events, though rare, include endometrial hyperplasia or bleeding, thromboembolic disorders such as deep‑vein thrombosis, severe allergic reactions, and, with prolonged use, an increased risk of uterine cancer. Patients should promptly report unusual vaginal bleeding, leg pain, shortness of breath, or signs of an allergic reaction to their clinician.

Menovag is contraindicated in women with a history of estrogen‑dependent cancers (e.g., breast or endometrial cancer), active or past thromboembolic disease, unexplained vaginal bleeding, or known hypersensitivity to estradiol or any excipients. It is also not intended for use in pregnant or breastfeeding women, and clinicians should assess each patient’s risk profile before prescribing.